Background Dupilumab, the first biological drug to be approved for the treatment of
moderate to severe atopic dermatitis in adolescents and adults, has shown good efficacy …

Atopic dermatitis (AD) is a chronic, inflammatory skin disorder that most frequently occurs in
children, but it can also affect adults. Even though most AD cases can be managed with …

Background Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-
4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in …

Background The efficacy and safety of upadacitinib in atopic dermatitis (AD) have been
defined in clinical trials, but no real-world data are currently available. We aimed to assess …

Background Dupilumab is the first biologic registered for the treatment of moderate‐to‐
severe atopic dermatitis (AD), and efficacy was shown in phase III clinical trials (primary …

Background: Dupilumab has been demonstrated to be an effective treatment for patients
with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real …

Objective The objective of this study was to assess the effectiveness and safety of dupilumab
in treating elderly patients with atopic dermatitis from baseline to 52 weeks. Methods A …

Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved
for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical …

Dupilumab is a first-in-class biologic approved by the European Medicines Agency and the
US Food and Drug Administration for the treatment of multiple atopic diseases, including …

Previously, we have reported short term effectiveness and safety of dupilumab in Korea. In
this study, we are trying to report the long-term effectiveness and safety of dupilumab in …